CUE-501 / Cue Biopharma, Boehringer Ingelheim - LARVOL DELTA

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire) - "Boehringer Ingelheim and Cue Biopharma...announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases....Under the terms of the agreement, Cue Biopharma’s technology will be leveraged to further research and advance the development of the candidate molecule. The terms of the multi-year collaboration also include the ability of the parties to expand research and potential development into various B cell targeting bispecifics encompassing autoimmune diseases."

Licensing / partnership • Immunology • Inflammation